elasomeran · Spikevax
Vaccine
Evidence outlook
Approved: COVID-19
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older (conditional marketing authorisation)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04470427 NCT04470427 · SARS-CoV-2 The blinded Part A was a large, randomized, quadruple-masked, placebo-controlled trial with a hard clinical primary endpoint: adjudicated, symptomatic and RT-PCR-confirmed COVID-19. The primary efficacy comparison was statistically significant in favor of elasomeran, with 55 cases among 14,287 recipients versus 744 among 14,164 placebo recipients; later portions of the study were open-label follow-up and booster evaluation. Registry: NCT04470427 | 3 | Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose (From Day 43 (14 days after second dose) up to approximately 7 months after the second dose); Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose (up to Day 7 (7 days after first dose)); Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose (Day 29 to Day 35 (from second dose to 7 days after second dose)); Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation (Day 1 (after dosing) through end of study (up to Day 759)); Parts A and B: Number of Participants With Serious AEs (SAEs) (Day 1 (after dosing) through end of study (up to Day 759)) 2022-12-29 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
View 2 more trials
NCT05436834 NCT05436834 · COVID-19 Registry: NCT05436834 | 3 | Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) (Up to Day 8 (7 days post-vaccination)); Number of Participants with Unsolicited Adverse Events (AEs) (Up to Day 29 (28 days after each injection)); Number of Participants with Medically-Attended AEs (MAAEs) (Up to Day 394 (12 months after last dose)); Number of Participants with Serious AEs (SAEs) (Up to Day 394 (12 months after last dose)); Number of Participants with Adverse Events of Special Interest (AESI) (Up to Day 394 (12 months after last dose)); Number of Participants with AEs Leading to Withdrawal (Up to Day 394 (12 months after last dose)); Geometric Mean (GM) of the Serum Antibody (Ab) Level against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration at Day 57; GM of the Serum Ab Level against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration at Day 29; Seroresponse Rate (SRR) against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration (Day 29); GM of the Serum Ab Level against Omicron XBB.1.5 after mRNA-1273.815 Administration (Up to Day 57) 2025-10-20 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT04860297 NCT04860297 · SARS-CoV-2 The study enrolled 234 participants in a single open-label group without randomization, blinding, or a placebo or active comparator. Its primary outcomes were descriptive safety measures and antibody concentrations rather than a randomized clinical comparison, so the findings provide limited evidence for elasomeran’s comparative effectiveness. Registry: NCT04860297 | 3 | Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs) (Up to 28 days post-vaccination); Parts A and B: Number of Healthy Participants With Unsolicited AEs (Up to 28 days post-vaccination); Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs) (Throughout the study period (up to Day 450)); Parts A and B: Number of Healthy Participants With MAAEs (Throughout the study period (up to Day 394)); Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs) (Throughout the study period (up to Day 450)); Parts A and B: Number of Healthy Participants With SAEs (Throughout the study period (up to Day 394)); Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis (Throughout the study period (up to Day 450)); Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis (Throughout the study period (up to Day 394)); Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal) (Throughout the study period (up to Day 450)); Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal) (Throughout the study period (up to Day 394)); Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection (Throughout the study period (up to Day 450)); Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection (Throughout the study period (up to Day 394)); Parts A and B: Number of SOT Participants With Solicited Local and Systemic Adverse Reactions (ARs) (7 days post-vaccination); Parts A and B: Number of Healthy Participants With Solicited Local and Systemic ARs (7 days post-vaccination); Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants (Day 57 (for unvaccinated participants)); Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3; Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series (28 days after BD injection (BD-Day 29)) 2023-05-22 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (9)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Elasomeran (Spikevax): this drug | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4396687 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Spikevax (elasomeran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.